Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 570 of 6351
-
New combo therapy shows promise for tough lung cancer
Disease control Recruiting nowThis study is a prospective, single arm, phase II clinical trial. We plan to include 36 newly diagnosed ES-SCLC patients who meet the inclusion criteria and receive induction therapy (tislelizumab+EP regimen, 4-6 cycles). After completing the induction therapy, efficacy evaluatio…
Phase 2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo aims to stall advanced stomach cancer
Disease control Recruiting nowThis is a single arm, open-label, phase II trial investigating the combination of ivonescimab with standard FOLFOX chemotherapy in 1L therapy for HER2- GEA.
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New balloon coated with drug could save limbs in severe artery disease
Disease control Stopped earlyThe objective of this study is to assess whether efficacy of the AcoArt Litos PCB is superior and whether safety of AcoArt Litos PCB is noninferior to the control device (FDA cleared PTA Balloon Catheter) regarding treatment of obstructions in the infrapopliteal arteries (located…
Sponsor: Acotec Scientific Co., Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Genetically modified t cells take on glioblastoma
Disease control Recruiting nowThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious dis…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control Not yet recruitingTo clarify the safety and efficacy of using uniform-sized drug-loaded embolic microspheres (E-TACE) of different particle sizes for graded embolization during TACE combined with Donafenib in the treatment of unresectable primary liver cancer. To determine whether this therapy can…
Sponsor: Xuhua Duan • Aim: Disease control
Last updated Jun 26, 2026 18:09 UTC
-
New drug combo aims to turn inoperable pancreatic cancer into operable tumors
Disease control Not yet recruitingThe goal of this interventional study is to learn about the clinical efficacy of sequential therapy (albumin paclitaxel, gemcitabine combined with PD-L1 antibodies, followed by liposomal irinotecan, oxaliplatin and 5-FU/LV combined with PD-L1 antibodies). The main questions it ai…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo aims to shrink breast tumors before surgery
Disease control Not yet recruitingThis study is a prospective, multicenter, single-arm, exploratory study. 30 patients with locally advanced HR+/HER2- breast cancer who have not received any treatment were recruited to receive apalutamide voraparib combined with chemotherapy for neoadjuvant therapy. This study ad…
Phase 2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New enzyme combo aims to boost leukemia treatment in High-Risk adults
Disease control Recruiting nowThis phase II trial tests the safety, side effects, and effectiveness of asparaginase Erwinia chrysanthemi during induction chemotherapy followed by consolidation chemotherapy in treating high-risk adults with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for recurrent throat cancer: Radiation-Immunotherapy combo shows promise
Disease control Recruiting nowThis single-arm, single-center phase II trial evaluates the safety and efficacy of a non-continuous radio-immunotherapy strategy for recurrent nasopharyngeal carcinoma (NPC) unsuitable for surgery. Induction consists of three fractions of low-dose radiotherapy (1.5 Gy ×3) plus hi…
Phase 2 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Liver cancer breakthrough: surgery or pills after shrinkage?
Disease control Not yet recruitingThis is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC). Participants first receive conversion therapy with transarterial chemoemboliz…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for bile duct cancer: experimental drug takes on chemo
Disease control Recruiting nowThe object of this trial is to test whether ivonescimab is superior to standard chemotherapy (FOLFOX regimen) for the treatment of patients with advanced biliary tract cancer after failure of a first line of chemotherapy. It is only open to patients who participated in the SAFIR-…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for rare overgrowth disorder: daily pill could tame symptoms
Disease control Recruiting nowThis study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spectrum (PROS).
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New stroke combo could boost recovery for medium clots
Disease control Recruiting nowPEARL-MeVO is an investigator-initiated, multicenter, prospective, randomized controlled, open-label, blinded endpoint (PROBE) clinical trial aiming at evaluating the efficacy and safety of primary intra-arterial thrombolysis in improving 90-day functional outcome in acute ischem…
Phase 3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New JN.1 COVID shot shows promise in High-Risk groups
Vaccine CompletedThis study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120 participants. This includes adults aged 65 and older, and ind…
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 13:02 UTC
-
Radiation that skips lymph nodes may help rectal cancer patients keep their rectum
Disease control Recruiting nowThis is a single-arm, prospective, multicenter study evaluating a novel neoadjuvant treatment strategy for patients with early, mid-low rectal adenocarcinoma that is microsatellite stable (MSS). Instead of irradiating regional lymph nodes, we deliver short-course radiotherapy (25…
Phase 2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could some breast cancer patients skip extra treatment? new trial investigates
Disease control Recruiting nowThis phase II trial tests reduced post surgery (adjuvant) therapy for patients with early breast cancer who have confirmed that the disease has responded completely (pathologic complete response) after pre surgical treatment (neoadjuvant) therapy and do not have any tumor genetic…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
App alerts COPD patients when their inhalers may be out of date
Disease control Recruiting nowAlthough COPD cannot be cured, managing COPD can help reduce symptoms control, slows progression of the disease, and may improve the quality of life. Management of COPD becomes less effective when healthcare professionals fail to prescribe appropriate inhaled therapies, due to po…
Phase 1 • Sponsor: University of Southampton • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can radiation plus immunotherapy shrink recurrent head and neck tumors before surgery?
Disease control Recruiting nowThe purpose of the Phase I study is to see if it is safe to use X-ray photon radiation (XRT) and proton radiation (PT) before surgery in patients with recurrent head and neck squamous cell carcinoma (rHNSCC). The purpose of the Phase II study is to see if using XRT or PT before …
Phase 1/2 • Sponsor: University of Cincinnati • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a depression drug tame the psychedelic trip without killing the benefits?
Symptom relief Not yet recruitingPsilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects. The benefit-risk ratio of psilocybin in treatment-resistant depression seems favorable, but needs to be confirmed. More…
Phase 2 • Sponsor: Centre Hospitalier St Anne • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
New hope for ulcerative colitis: duvakitug enters phase 3 trial
Disease control Recruiting nowThis is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC